Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (30)

1

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

enthalten in: Cancer | 2024

von Nooka, A. | Rodriguez, C. | Mateos, M. | +9

2

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

3

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

4

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation

enthalten in: Blood advances | 2024

von Frerichs, K. | Verkleij, C. | Mateos, M. | +21

5

Management of multiple myeloma-related renal impairment : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2023

von Dimopoulos, M. | Merlini, G. | Bridoux, F. | +25

6

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

enthalten in: EBioMedicine | 2023

von Hiemstra, I. | Santegoets, K. | Janmaat, M. | +17

7

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

enthalten in: Cancer | 2023

von Martin, T. | Mateos, M. | Nooka, A. | +12

8

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

9

Teclistamab in Relapsed or Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2022

von Moreau, P. | Garfall, A. | van de Donk, N. | +31

CommentIn: N Engl J Med. 2022 Aug 11;387(6):558-561. - PMID 35947712

10

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas

enthalten in: Cancer research communications | 2022

von Martens, A. | Rietveld, J. | de Boer, R. | +12